CN111603176A - Semi-implanted optical blood glucose monitoring method, terminal equipment and server - Google Patents
Semi-implanted optical blood glucose monitoring method, terminal equipment and server Download PDFInfo
- Publication number
- CN111603176A CN111603176A CN202010449335.7A CN202010449335A CN111603176A CN 111603176 A CN111603176 A CN 111603176A CN 202010449335 A CN202010449335 A CN 202010449335A CN 111603176 A CN111603176 A CN 111603176A
- Authority
- CN
- China
- Prior art keywords
- blood glucose
- terminal equipment
- value
- real
- server
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008280 blood Substances 0.000 title claims abstract description 311
- 210000004369 blood Anatomy 0.000 title claims abstract description 310
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 title claims abstract description 209
- 239000008103 glucose Substances 0.000 title claims abstract description 209
- 230000003287 optical effect Effects 0.000 title claims abstract description 77
- 238000012544 monitoring process Methods 0.000 title claims abstract description 74
- 238000000034 method Methods 0.000 title claims abstract description 59
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims abstract description 74
- 102000004877 Insulin Human genes 0.000 claims abstract description 37
- 108090001061 Insulin Proteins 0.000 claims abstract description 37
- 229940125396 insulin Drugs 0.000 claims abstract description 37
- 238000002347 injection Methods 0.000 claims abstract description 35
- 239000007924 injection Substances 0.000 claims abstract description 35
- 238000004891 communication Methods 0.000 claims abstract description 32
- 238000004422 calculation algorithm Methods 0.000 claims abstract description 27
- 238000006243 chemical reaction Methods 0.000 claims abstract description 20
- 238000004590 computer program Methods 0.000 claims description 22
- 239000003814 drug Substances 0.000 claims description 21
- 230000005540 biological transmission Effects 0.000 claims description 20
- 230000002159 abnormal effect Effects 0.000 claims description 14
- 239000007788 liquid Substances 0.000 claims description 14
- 208000013016 Hypoglycemia Diseases 0.000 claims description 6
- 238000012790 confirmation Methods 0.000 claims description 6
- 238000011160 research Methods 0.000 abstract description 6
- 230000008901 benefit Effects 0.000 abstract description 2
- 230000000694 effects Effects 0.000 description 17
- 238000001514 detection method Methods 0.000 description 14
- 206010012601 diabetes mellitus Diseases 0.000 description 11
- 230000006870 function Effects 0.000 description 11
- 238000012545 processing Methods 0.000 description 9
- 229940079593 drug Drugs 0.000 description 7
- 235000016709 nutrition Nutrition 0.000 description 7
- 235000005911 diet Nutrition 0.000 description 6
- 210000003722 extracellular fluid Anatomy 0.000 description 6
- 238000007619 statistical method Methods 0.000 description 6
- 238000003745 diagnosis Methods 0.000 description 5
- 230000035764 nutrition Effects 0.000 description 5
- 230000037213 diet Effects 0.000 description 4
- 238000002513 implantation Methods 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 210000002381 plasma Anatomy 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 208000003443 Unconsciousness Diseases 0.000 description 3
- 230000008878 coupling Effects 0.000 description 3
- 238000010168 coupling process Methods 0.000 description 3
- 238000005859 coupling reaction Methods 0.000 description 3
- 230000002354 daily effect Effects 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 230000002218 hypoglycaemic effect Effects 0.000 description 3
- 235000012054 meals Nutrition 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 206010010071 Coma Diseases 0.000 description 2
- 102000017011 Glycated Hemoglobin A Human genes 0.000 description 2
- 210000001015 abdomen Anatomy 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 230000036760 body temperature Effects 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 238000013079 data visualisation Methods 0.000 description 2
- 238000005034 decoration Methods 0.000 description 2
- 230000000378 dietary effect Effects 0.000 description 2
- 235000006694 eating habits Nutrition 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 235000012631 food intake Nutrition 0.000 description 2
- 230000002641 glycemic effect Effects 0.000 description 2
- 230000031700 light absorption Effects 0.000 description 2
- 210000004880 lymph fluid Anatomy 0.000 description 2
- 238000007726 management method Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 238000000691 measurement method Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000010827 pathological analysis Methods 0.000 description 2
- 230000035790 physiological processes and functions Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 235000019640 taste Nutrition 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 108010014663 Glycated Hemoglobin A Proteins 0.000 description 1
- 240000008790 Musa x paradisiaca Species 0.000 description 1
- 235000018290 Musa x paradisiaca Nutrition 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 230000010267 cellular communication Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000013500 data storage Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- 235000005686 eating Nutrition 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 208000004104 gestational diabetes Diseases 0.000 description 1
- 230000010030 glucose lowering effect Effects 0.000 description 1
- 230000004153 glucose metabolism Effects 0.000 description 1
- 108091005995 glycated hemoglobin Proteins 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 238000012806 monitoring device Methods 0.000 description 1
- 230000008054 signal transmission Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 210000000707 wrist Anatomy 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
- A61B5/1455—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue using optical sensors, e.g. spectral photometrical oximeters
- A61B5/1459—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue using optical sensors, e.g. spectral photometrical oximeters invasive, e.g. introduced into the body by a catheter
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
- A61B5/14532—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue for measuring glucose, e.g. by tissue impedance measurement
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/74—Details of notification to user or communication with user or patient ; user input means
- A61B5/746—Alarms related to a physiological condition, e.g. details of setting alarm thresholds or avoiding false alarms
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Physics & Mathematics (AREA)
- Medical Informatics (AREA)
- Surgery (AREA)
- Biophysics (AREA)
- Pathology (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Optics & Photonics (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Emergency Medicine (AREA)
- Physiology (AREA)
- Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)
Abstract
The invention provides a semi-implanted optical blood glucose monitoring method, terminal equipment and a server, wherein the method comprises the following steps: the acquisition end acquires optical reflection signals through the infrared transceiver implanted under the skin and performs photoelectric conversion on the optical reflection signals to obtain target current digital signals; the terminal equipment receives a target current digital signal sent by a wireless communication module of the acquisition end directly or through a server; and the terminal equipment converts the value of the target current digital signal and a preset glucose calibration algorithm to obtain the real-time blood glucose value. The invention realizes dynamic monitoring of the blood sugar content in the body of the user through implanted acquisition, improves the real-time performance and accuracy of blood sugar monitoring, provides user experience, realizes emergency reminding, insulin emergency injection, automatic calling for help and contact with emergency contacts through a matched terminal, records various life events for medical research, and benefits more people.
Description
Technical Field
The invention relates to the technical field of medical instruments, in particular to a semi-implanted optical blood glucose monitoring method, terminal equipment and a server.
Background
Blood glucose monitoring is the scientific basis for diagnosing diabetes, evaluating glucose metabolism level, making and adjusting glucose-lowering schemes, and the like. The clinical blood sugar monitoring method mainly comprises capillary blood sugar monitoring, dynamic blood sugar monitoring, glycosylated hemoglobin detection and the like. Among them, the result of glycated hemoglobin (HbA1c) assay is a gold standard reflecting long-term glycemic control level, but has limitations due to its delayed effect on evaluating therapeutic effects and its inability to measure at home; the patient self-blood glucose monitoring is used as a basic form of blood glucose monitoring, but the contradiction that insufficient monitoring frequency can influence judgment, and too frequent monitoring can increase pain to cause anxiety of the patient exists.
The regularity of glucose concentration changes after exercise and after meals is not manageable and if insulin is injected in excess, patient death from hypoglycemia coma is unpredictable. Continuous monitoring of diabetic patients by carrying a dynamic blood glucose monitoring device is generally considered by the international academia as the best way of diagnosis and treatment. Dynamic blood glucose monitoring (CGMS) can identify asymptomatic hypoglycemia, the cause of death of about 2% of diabetic patients being hypoglycemia. In addition, the type I and part of severe type II diabetes patients are sensitive to abnormal fluctuation of blood sugar data in different periods, so the dynamic blood sugar map provided by the CGMS is particularly important for clinical diabetes treatment and education, and the life quality of the patients can be effectively improved.
In order to realize dynamic real-time monitoring of blood glucose concentration, minimally invasive and non-invasive methods such as a body fluid affected side algorithm and the like are available, but the problems of instantaneity, accuracy and the like of blood glucose monitoring cannot be effectively solved, and the user experience is influenced by trauma.
Disclosure of Invention
The invention aims to provide a semi-implanted optical blood glucose monitoring method, terminal equipment and a server, which can realize dynamic monitoring of blood glucose content in a user body through implanted acquisition, improve the real-time performance and accuracy of blood glucose monitoring and provide user experience.
The technical scheme provided by the invention is as follows:
the invention provides a semi-implanted optical blood glucose monitoring method, which comprises the following steps:
the collecting end collects optical reflection signals through an infrared receiving and transmitting device implanted under the skin and carries out photoelectric conversion on the optical reflection signals to obtain target current digital signals;
the terminal equipment receives a target current digital signal sent by a wireless communication module of the acquisition end directly or through a server;
and the terminal equipment converts the value according to a preset glucose calibration algorithm and the target current digital signal to obtain the real-time blood glucose value.
Further, the step of converting the terminal device according to a preset glucose calibration algorithm and the value of the target current digital signal to obtain the real-time blood glucose value by the terminal device includes:
the terminal device displays the real-time blood glucose values and/or the retrospective blood glucose values.
Further, the method for converting the real-time blood glucose value by the terminal device according to the preset glucose calibration algorithm and the value of the target current digital signal further comprises the following steps:
the terminal equipment generates prompt information to remind abnormal blood sugar when the real-time blood sugar value exceeds a preset numerical range;
and if the closing times of the terminal equipment for reminding the abnormal blood glucose reach the preset times within the preset time, generating prompt information to remind equipment faults.
Further, the terminal device generates prompt information to prompt abnormal blood sugar when the real-time blood sugar value exceeds a preset value range, and the prompt comprises the following steps:
the terminal equipment carries out blood sugar excess reminding when the real-time blood sugar value is higher than a preset blood sugar maximum value;
when the real-time blood glucose value is lower than a preset blood glucose minimum value, the terminal equipment reminds of too low blood glucose;
the terminal equipment comprises the following steps after the blood sugar excess reminding is carried out:
the terminal equipment acquires the input blood glucose event information and calculates the insulin demand according to the real-time blood glucose value and the blood glucose event information;
the terminal equipment generates an injection instruction according to the insulin demand when acquiring the injection confirmation information, and sends the injection instruction to an execution end which is arranged on the body surface and is provided with a micro pump and a liquid storage cavity;
and the execution end injects the insulin medicament in the micro pump into the body of the user according to the injection instruction.
The invention also provides a semi-implanted optical blood glucose monitoring method, which comprises the following steps:
the collecting end collects optical reflection signals through an infrared receiving and transmitting device implanted under the skin and carries out photoelectric conversion on the optical reflection signals to obtain target current digital signals;
the server acquires a target current digital signal from the acquisition end through the wireless transmission module;
and the server converts the digital value of the target current digital signal according to a preset glucose calibration algorithm to obtain a real-time blood glucose value.
Further, the server converts the value according to a preset glucose calibration algorithm and the target current digital signal to obtain a real-time blood glucose value, and then comprises the following steps:
and the server sends the real-time blood glucose value to the terminal equipment, and the terminal equipment displays the real-time blood glucose value and/or the retrospective blood glucose value.
Further, the server converts the value according to a preset glucose calibration algorithm and the target current digital signal to obtain a real-time blood glucose value, and then the method further comprises the following steps:
the server generates prompt information when the real-time blood glucose value exceeds a preset numerical range and sends the prompt information to the terminal equipment to remind of blood glucose abnormity;
and the server generates prompt information and sends the prompt information to the terminal equipment to remind equipment faults when receiving the closing prompt information fed back by the terminal equipment and the closing times reach the preset times within the preset time.
Further, the step of generating, by the server, a prompt message when the real-time blood glucose value exceeds a preset numerical range includes:
the server generates and sends first prompt information to the terminal equipment to remind the terminal equipment of excessive blood sugar when the real-time blood sugar value is higher than a preset maximum blood sugar value;
the server generates and sends second prompt information to the terminal equipment to remind the user of the too low blood sugar when the real-time blood sugar value is lower than a preset minimum blood sugar value;
the terminal equipment comprises the following steps after the terminal equipment reminds of excessive blood sugar:
the server acquires the input blood glucose event information from the terminal equipment and calculates the insulin demand according to the real-time blood glucose value and the blood glucose event information;
the server generates an injection instruction according to the insulin demand when acquiring the injection confirmation information sent by the terminal equipment, and sends the injection instruction to an execution end which is arranged on the body surface and is provided with a micro pump and a liquid storage cavity;
and the execution end injects the insulin medicament in the micro pump into the body of the user according to the injection instruction.
The invention also provides a terminal device, which comprises a processor, a memory and a computer program stored in the memory and capable of running on the processor, wherein the processor is used for executing the computer program stored in the memory to realize the operation executed by the semi-implantation type optical blood glucose monitoring method.
The invention also provides a server, which comprises a processor, a memory and a computer program stored in the memory and capable of running on the processor, wherein the processor is used for executing the computer program stored in the memory to realize the operation executed by the semi-implantation type optical blood glucose monitoring method.
By the semi-implanted optical blood glucose monitoring method, the terminal equipment and the server, the blood glucose content in the body of the user can be dynamically monitored through implanted acquisition, the real-time performance and the accuracy of blood glucose monitoring are improved, and the user experience is provided.
Drawings
The above features, technical features, advantages and implementations of a semi-implantable optical blood glucose monitoring method, a terminal device and a server will be further described in the following detailed description of preferred embodiments with reference to the accompanying drawings.
FIG. 1 is a flow chart of one embodiment of a semi-implantable optical blood glucose monitoring method of the present invention;
FIG. 2 is a flow chart of another embodiment of a semi-implantable optical blood glucose monitoring method of the present invention;
FIG. 3 is a flow chart of another embodiment of a semi-implantable optical blood glucose monitoring method of the present invention;
FIG. 4 is a flow chart of another embodiment of a semi-implantable optical blood glucose monitoring method of the present invention;
FIG. 5 is a flow chart of another embodiment of a semi-implantable optical blood glucose monitoring method of the present invention;
FIG. 6 is a flow chart of another embodiment of a semi-implantable optical blood glucose monitoring method of the present invention;
FIG. 7 is a flow chart of another embodiment of a semi-implantable optical blood glucose monitoring method of the present invention;
fig. 8 is a flow chart of another embodiment of a semi-implantable optical blood glucose monitoring method of the present invention.
Detailed Description
In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the following description will be made with reference to the accompanying drawings. It is obvious that the drawings in the following description are only some examples of the invention, and that for a person skilled in the art, other drawings and embodiments can be derived from them without inventive effort.
For the sake of simplicity, the drawings only schematically show the parts relevant to the present invention, and they do not represent the actual structure as a product. In addition, in order to make the drawings concise and understandable, components having the same structure or function in some of the drawings are only schematically illustrated or only labeled. In this document, "one" means not only "only one" but also a case of "more than one".
In one embodiment of the present invention, as shown in fig. 1, a semi-implantable optical blood glucose monitoring method includes:
s111, collecting optical reflection signals by a collecting end through an infrared receiving and transmitting device implanted under the skin, and carrying out photoelectric conversion on the optical reflection signals to obtain target current digital signals;
specifically, the acquisition end comprises an infrared receiving and transmitting device, a control chip, a wireless transmission module (comprising a 5G module), a power supply module, a shell and a wireless charging module, wherein the infrared receiving and transmitting device comprises an LED infrared light source emitter and a photoelectric detection module. The power supply module comprises a battery and a power management circuit and is responsible for supplying power to the infrared receiving and transmitting equipment, the control chip and the wireless transmission module, and the battery can adopt a storage battery. Because the collection end is implanted subcutaneously, inconvenient taking out at any time, consequently accessible wireless charging module charges power module's battery when power module electric quantity is not enough. The shell is made of a material with good biocompatibility, and all modules except the implanted infrared transceiving equipment and the wireless charging module are covered with the control chip, the wireless transmission module (including a 5G module) and the power supply module.
Preferably, the measurement interval time of the LED infrared light source emitter to the blood sugar of the human body can be adjusted, the LED infrared light source emitter can enter a dormant state to reduce power consumption when blood sugar detection is not needed, and the LED infrared light source emitter can be awakened by terminal equipment or a server at any time.
Wherein, glucose in blood mainly dissolves in plasma, and the principle of acquiring the target current digital signal by collecting the optical reflection signal through the infrared transceiver device is as follows: after the control chip controls the LED infrared light source transmitter to periodically transmit infrared light beams to human interstitial fluid (liquid existing in intercellular substance and including fibers, matrix and fluid substances (interstitial fluid, lymph fluid, blood plasma and the like)), the photoelectric detection module receives the infrared light beams reflected back by the human interstitial fluid and carries out photoelectric conversion on the reflected infrared light beams to obtain corresponding target current digital signals.
Preferably, the collecting end is worn on the body of the patient, and can be an arm, an abdomen and the like, and the collecting end needs to be waterproof, has the smallest volume and the simplest structure (the failure rate is correspondingly reduced).
S112, the terminal equipment receives a target current digital signal sent by a wireless communication module of the acquisition end directly or through a server;
specifically, the terminal device includes, but is not limited to, a device in which wearable smart devices such as a smart phone, a tablet, a computer, a smart television, and a bracelet are equipped with blood glucose matching management software. The photoelectric detection module of the acquisition end carries out protocol conversion on the digitized target current digital signal and then uploads the converted signal to the terminal equipment through the wireless transmission module, or the digitized target current digital signal is directly uploaded to the server through the wireless transmission module, and the server carries out protocol conversion and then uploads the converted signal to the terminal equipment through the wireless transmission module.
Preferably, because the types and the number of the terminal devices are various, different signal transmission modes are also considered, the acquisition end directly uploads the digital target current signals to the server, other processes can be processed by the server, even the server can complete software operation, and the data and monitoring functions are resolved, so that fewer instructions need to be executed by the acquisition end, less power consumption is required, the frequency of battery replacement can be reduced, and the service life of the acquisition end is greatly prolonged.
And S113, the terminal equipment converts the value of the target current digital signal and a preset glucose calibration algorithm to obtain a real-time blood glucose value.
Specifically, since blood glucose is low in blood, the absorption of light is weak, and the brightness values (chromaticity values) of the infrared reflection spectrum data are different in the case of different blood glucose concentrations. The acquisition terminal is wirelessly transmitted to the terminal equipment through a wireless transmission module (preferably a 5G wireless module) or transmitted to the server and then forwarded to the terminal equipment. At this time, the application software on the terminal device performs digital signal data processing on the target current digital signal to calculate the measured blood glucose level.
The preset glucose calibration algorithm is written according to specifications of purchased implanted infrared transceiver devices. Different parameters of different implanted infrared transceiving equipment are different, the drift of the precision and the measured value along with the parameters of time, temperature, humidity and the like are different, and different preset glucose calibration algorithms need to be designed.
In the embodiment, the optical reflection signals are acquired in real time through the implanted infrared transceiving equipment, and then the real-time blood sugar value of the user can be obtained through real-time conversion. Convenient continuous autonomous detection is realized, and compared with the existing equipment, the influence on the daily activities of the user is greatly reduced.
Preferably, aiming at different individuals, the blood sugar value is calibrated according to externally measured parameters such as body temperature, environmental temperature and the like by combining an optical measurement method so as to accurately calculate the blood sugar concentration and improve the measurement precision of the optically measured blood sugar value. The blood glucose value capable of reflecting the health condition of the human body is measured in an optical mode, so that comprehensive pathological analysis can be performed on a user, and the method can be used as a timely and effective diagnosis, diagnosis and prevention method.
In one embodiment of the present invention, as shown in fig. 2, a semi-implantable optical blood glucose monitoring method includes:
s121, collecting optical reflection signals by a collecting end through an infrared receiving and transmitting device implanted under the skin, and carrying out photoelectric conversion on the optical reflection signals to obtain target current digital signals;
s122, the terminal equipment receives a target current digital signal sent by a wireless communication module of the acquisition end directly or through a server;
s123, the terminal equipment converts the value of the target current digital signal and a preset glucose calibration algorithm to obtain a real-time blood glucose value;
s124, the terminal device displays the real-time blood glucose value and/or the retrospective blood glucose value.
Specifically, the terminal device converts the real-time blood glucose value to obtain a real-time blood glucose value, and stores the real-time blood glucose value. Then, the real-time blood glucose level is displayed in accordance with the user operation, or the retrospective blood glucose level is switched to be displayed in accordance with the user operation. Retrospective blood glucose value is blood glucose value which is required to be reviewed and checked by a user after the distance detection time reaches a preset time interval, and data visualization is realized by installing supporting software on terminal equipment. Preferably, the predetermined time interval is set to half an hour for life safety of the diabetic.
Preferably, the terminal device not only displays the monitored real-time blood glucose value and retrospective blood glucose value, but also can perform intelligent statistical analysis according to all stored blood glucose values (including the real-time blood glucose value and the retrospective blood glucose value), and presents the final statistical analysis result to the patient and the guardian, so that the blood glucose monitoring information is displayed in real time through the portability characteristic of the terminal device, and the user experience is improved.
In this embodiment, combine to gather end, terminal equipment and/or server, accomplish the dynamic monitoring of blood glucose, but the retrospective blood glucose value is looked over to the arbitrary time to look over the real-time blood glucose value in real time, the portability characteristic through terminal equipment shows blood glucose monitoring information immediately, promotes user and uses experience.
In one embodiment of the present invention, as shown in fig. 3, a semi-implantable optical blood glucose monitoring method includes:
s131, collecting optical reflection signals by a collecting end through an infrared receiving and transmitting device implanted under the skin, and carrying out photoelectric conversion on the optical reflection signals to obtain target current digital signals;
s132, the terminal equipment receives a target current digital signal sent by a wireless communication module of the acquisition end directly or through a server;
s133, the terminal equipment converts the value of the target current digital signal and a preset glucose calibration algorithm to obtain a real-time blood glucose value;
s134, the terminal equipment generates prompt information to remind abnormal blood sugar when the real-time blood sugar value exceeds a preset value range and the terminal equipment is not closed within a preset time length;
and S135, if the closing times of the abnormal blood glucose reminding by the terminal equipment reach the preset times within the preset time, generating prompt information to remind equipment faults.
Specifically, the terminal device reminds in a voice, vibration and interface prompting mode, wherein in order to distinguish blood sugar abnormity reminding and device fault reminding, the terminal device distinguishes reminding through different reminding contents, for example, the terminal device reminds blood sugar abnormity through voice, and device fault reminding is carried out through vibration. Of course, the terminal device can perform blood sugar abnormality reminding and device failure reminding by vibration, and only the vibration frequencies are different, and other ways of distinguishing and reminding different reminding contents are within the protection scope of the present invention, and will not be described in detail herein.
The real-time blood sugar value generally does not exceed a preset blood sugar maximum value and a preset blood sugar minimum value of a medical clinical observation value, and at the minimum value, because the brain cannot obtain blood sugar supply, a person can die after being unconscious, and if the measured value frequently exceeds a preset upper limit value and a preset lower limit value (namely the preset value range of the invention), the terminal equipment can generate prompt information to remind abnormal blood sugar. If the real situation of the patient is that no critical phenomenon exists and the self-feeling physical state is normal, the reminding can be turned off, timing is started at the initial moment of the abnormal reminding of the excessive blood sugar, and if the number of times of turning off the reminding reaches the preset number of times within the preset time length, the terminal equipment generates prompt information to carry out equipment fault reminding so as to remind the user to maintain or replace the acquisition end in time.
In one embodiment of the present invention, as shown in fig. 4, a semi-implantable optical blood glucose monitoring method includes:
s141, collecting optical reflection signals by a collecting end through an infrared receiving and transmitting device implanted under the skin, and carrying out photoelectric conversion on the optical reflection signals to obtain target current digital signals;
s142, the terminal equipment receives a target current digital signal sent by a wireless communication module of the acquisition end directly or through a server;
s143, the terminal equipment converts the value of the target current digital signal and a preset glucose calibration algorithm to obtain a real-time blood glucose value;
s144, the terminal equipment reminds of excessive blood sugar when the real-time blood sugar value is higher than the preset maximum blood sugar value;
s145, the terminal equipment acquires the input blood glucose event information, and calculates the insulin demand according to the real-time blood glucose value and the blood glucose event information;
s146, when the injection confirmation information is obtained, the terminal equipment generates an injection instruction according to the insulin demand and sends the injection instruction to an execution end which is arranged on the body surface and is provided with a micro pump and a liquid storage cavity;
s147, injecting the insulin medicament in the micro pump into the body of the user by the execution end according to the injection instruction;
s148, when the real-time blood sugar value is lower than the preset minimum blood sugar value, the terminal equipment reminds that the blood sugar is too low;
s149 the terminal equipment closes the abnormal blood sugar reminding within a preset time period to a preset number, and then prompt information is generated to remind equipment faults.
Specifically, the terminal device may obtain information about related events that affect blood glucose changes, that is, blood glucose event information, where the information about blood glucose events includes, but is not limited to, event types corresponding to blood glucose activity events and occurrence times and numbers corresponding to the event types, the information about blood glucose activity events includes, but is not limited to, meals, medicines, and sports, and many similar activity events may be included, such as watching a stimulating movie, singing a song, running, and the like.
The software installed on the terminal equipment has options for the user to select and fill in, the filling mode can be typewriting, voice, handwriting input board and the like, and the patient generally records the blood glucose activity events such as diet, exercise, medication and the like every day according to the requirement of the doctor. The blood glucose activity events such as diet and medication need to be recorded by the patient in a matching way, for example, the patient takes one banana, then the blood glucose condition can be recorded in real time, for example, the patient drinks one cup of tea, the blood glucose change condition can be recorded and monitored in real time, the blood glucose activity events are recorded, early warning and prompting can be conveniently carried out in a short time, and the blood glucose activity events which are not suitable for the user can be analyzed in a personalized way for a long time and are suitable for the user to do frequently. Illustratively, the corresponding glycemic index is output according to the food name input by the user, and the corresponding safe eating amount is output based on the blood sugar value of the current user.
The execution end comprises a central processing unit for storing control programs and operation data and a processor of a storage element; a wireless communication module for sending and receiving injection instructions; a display for displaying the remaining amount of insulin medication to a user; a battery for providing power to the execution end; the insulin pump comprises a liquid storage cavity for storing insulin medicine and a micro pump for extracting the insulin medicine from the liquid storage cavity and injecting the insulin medicine into a user body.
When the real-time blood sugar value exceeds the preset value range, namely when the real-time blood sugar value is lower than the preset blood sugar minimum value, if the terminal equipment is not closed within the preset time length for reminding, prompt information is generated to remind that the blood sugar is too low, and a user can conveniently eat and supplement glucose in time. When the real-time blood sugar value is higher than the maximum preset blood sugar value, if the prompt message is generated during the reminding when the reminding is not closed within the preset time length, the reminding of the excessive blood sugar is carried out, in addition, the terminal equipment acquires the input blood sugar event information, then the terminal equipment calculates the insulin demand according to the real-time blood sugar value and the blood sugar event information, the terminal equipment generates an injection instruction according to the insulin demand when acquiring the confirmed injection information of the user, the injection instruction is sent to an execution end which is arranged on the body surface and provided with a micropump and a liquid storage cavity, and the execution end injects the insulin medicine in the micropump into the body of the user according to the injection instruction.
Preferably, the application software can be installed on the terminal equipment of the user such as a researcher, a doctor, a family member, a patient and a friend, and because of the privacy of the patient, if the blood sugar value needs to be shared to other people, the terminal equipment owner needs to share the login account password of the application software to other people.
The terminal equipment not only realizes core functions of dynamic monitoring, data query, waveform display and the like, but also can carry out intelligent statistical analysis on the monitored data, simplifies the operation of the patient, provides a more visual and concise feedback result for the patient, and can realize functions of dynamic monitoring, safe reminding, emergency call, emergency notification of family members and the like of the blood glucose data. Illustratively, if the patient is older and can carry the bracelet with him or her, this bracelet has the function of automatic call 120 and notice urgent contact, and like this, this patient if coma or unconsciousness because of hypoglycemia, can have life danger, can make automatic call 120 and notice urgent contact more conveniently, more in time through the bracelet, guarantee patient's life safety.
In one embodiment of the present invention, as shown in fig. 5, a semi-implantable optical blood glucose monitoring method includes:
s211, collecting optical reflection signals by a collecting end through an infrared receiving and transmitting device implanted under the skin, and carrying out photoelectric conversion on the optical reflection signals to obtain target current digital signals;
specifically, the acquisition end comprises an infrared receiving and transmitting device, a control chip, a wireless transmission module (comprising a 5G module), a power supply module, a shell and a wireless charging module, wherein the infrared receiving and transmitting device comprises an LED infrared light source emitter and a photoelectric detection module. The power supply module comprises a battery and a power management circuit and is responsible for supplying power to the infrared receiving and transmitting equipment, the control chip and the wireless transmission module, and the battery can adopt a storage battery. Because the collection end is implanted subcutaneously, inconvenient taking out at any time, consequently accessible wireless charging module charges power module's battery when power module electric quantity is not enough. The shell is made of a material with good biocompatibility, and all modules except the implanted infrared transceiving equipment and the wireless charging module are covered with the control chip, the wireless transmission module (including a 5G module) and the power supply module.
Preferably, the measurement interval time of the LED infrared light source emitter to the blood sugar of the human body can be adjusted, the LED infrared light source emitter can enter a dormant state to reduce power consumption when blood sugar detection is not needed, and the LED infrared light source emitter can be awakened by terminal equipment or a server at any time.
Wherein, glucose in blood mainly dissolves in plasma, and the principle of acquiring the target current digital signal by collecting the optical reflection signal through the infrared transceiver device is as follows: after the control chip controls the LED infrared light source transmitter to periodically transmit infrared light beams to human interstitial fluid (liquid existing in intercellular substance and including fibers, matrix and fluid substances (interstitial fluid, lymph fluid, blood plasma and the like)), the photoelectric detection module receives the infrared light beams reflected back by the human interstitial fluid and carries out photoelectric conversion on the reflected infrared light beams to obtain corresponding target current digital signals.
Preferably, the collecting end is worn on the body of the patient, and can be an arm, an abdomen and the like, and the collecting end needs to be waterproof, has the smallest volume and the simplest structure (the failure rate is correspondingly reduced).
S212, the server acquires a target current digital signal from the acquisition end through the wireless transmission module;
specifically, the server may be a local server, or may be a cloud server. The photoelectric detection module of the acquisition end directly uploads the digitized target current digital signal to the server through the wireless transmission module.
And S213, the server converts the value of the target current digital signal and a preset glucose calibration algorithm to obtain a real-time blood glucose value.
Specifically, since blood glucose is low in blood, the absorption of light is weak, and the brightness values (chromaticity values) of the infrared reflection spectrum data are different in the case of different blood glucose concentrations. The acquisition terminal is wirelessly transmitted to the terminal equipment through a wireless transmission module (preferably a 5G wireless module) or transmitted to the server and then forwarded to the terminal equipment. At this time, the application software on the terminal device performs digital signal data processing on the target current digital signal to calculate the measured blood glucose level.
The preset glucose calibration algorithm is written according to specifications of purchased implanted infrared transceiver devices. Different parameters of different implanted infrared transceiving equipment are different, the drift of the precision and the measured value along with the parameters of time, temperature, humidity and the like are different, and different preset glucose calibration algorithms need to be designed.
In this embodiment, gather the internal optical reflection signal of user through LED infrared light source transmitter in real time, and then the server can real-time conversion obtain user's real-time blood sugar value, then, the server sends the real-time blood sugar value that the monitoring obtained for user terminal, because gather the end implantation subcutaneous, the user only needs portable terminal equipment can monitor the internal blood sugar content of self anytime and anywhere, guarantees that user's is healthy and improves user and use experience. Convenient continuous autonomous detection is realized, and compared with the existing equipment, the influence on the daily activities of the user is greatly reduced.
In addition, the server is adopted to collect the blood sugar value, and clinical big data research is also conveniently carried out, the blood sugar value data of an individual is generally useful for the treatment of patients, and the blood sugar value data of a group has great significance for the clinical research. The acquisition end directly uploads a digital target current digital signal to the server, the acquisition end uploads the digital target current digital signal to the terminal equipment through the wireless transmission module after protocol conversion is carried out by the server, the communication protocol adopted by the acquisition end due to different terminal equipment types can be reduced, different communication protocols are additionally stored and different wireless communication modules are additionally arranged, other processes can be processed by the server, even software operation can be completed by the server, data calculation and monitoring functions are solved, the number of instructions required to be executed by the acquisition end is reduced, the power consumption is reduced, the frequency of battery replacement can be reduced, and the service life of the acquisition end is greatly prolonged.
Preferably, aiming at different individuals, the blood sugar value is calibrated according to externally measured parameters such as body temperature, environmental temperature and the like by combining an optical measurement method so as to accurately calculate the blood sugar concentration and improve the measurement precision of the optically measured blood sugar value. The blood glucose value capable of reflecting the health condition of the human body is measured in an optical mode, so that comprehensive pathological analysis can be performed on a user, and the method can be used as a timely and effective diagnosis, diagnosis and prevention method.
In an embodiment of the present invention, as shown in fig. 6, a semi-implantable optical blood glucose monitoring method includes:
s221, an acquisition end acquires optical reflection signals through an infrared transceiver implanted under the skin and performs photoelectric conversion on the optical reflection signals to obtain target current digital signals;
s222, the server acquires a target current digital signal from the acquisition end through the wireless transmission module;
s223, the server converts the value of the target current digital signal and a preset glucose calibration algorithm to obtain a real-time blood glucose value;
s224, the server sends the real-time blood sugar value to the terminal equipment, and the terminal equipment displays the real-time blood sugar value and/or the retrospective blood sugar value.
Specifically, the server converts the real-time blood glucose value to obtain a real-time blood glucose value, and stores the real-time blood glucose value. Then, the real-time blood glucose level is displayed in accordance with the user operation, or the retrospective blood glucose level is switched to be displayed in accordance with the user operation. Retrospective blood glucose value is blood glucose value which is required to be reviewed and checked by a user after the distance detection time reaches a preset time interval, and data visualization is realized by installing supporting software on terminal equipment. Preferably, the predetermined time interval is set to half an hour for life safety of the diabetic.
Preferably, the terminal device not only displays the monitored real-time blood glucose value and retrospective blood glucose value, but also can perform intelligent statistical analysis according to all stored blood glucose values (including the real-time blood glucose value and the retrospective blood glucose value), and presents the final statistical analysis result to the patient and the guardian, so that the blood glucose monitoring information is displayed in real time through the portability characteristic of the terminal device, and the user experience is improved.
In this embodiment, combine collection end, terminal equipment and server, accomplish the dynamic monitoring of blood sugar, but the retrospective blood sugar value is looked over to the arbitrary time to look over the real-time blood sugar value in real time, show blood sugar monitoring information immediately through terminal equipment's portability characteristic, promote user and use experience. Because the collection end is implanted subcutaneously, the user only needs to carry the terminal equipment and send the real-time blood sugar value converted by the server to the terminal equipment, the blood sugar content in the body of the user can be monitored at any time and any place, the body health of the user is ensured, and the use experience of the user is improved. In addition, the server can generate a dynamic blood sugar map to reflect the fluctuation trend of the blood sugar of the patient, and data statistics and analysis are carried out after one-time monitoring is finished so as to evaluate the blood sugar level of the patient.
In an embodiment of the present invention, as shown in fig. 7, a semi-implantable optical blood glucose monitoring method includes:
s231, collecting optical reflection signals by a collecting end through an infrared receiving and transmitting device implanted under the skin, and carrying out photoelectric conversion on the optical reflection signals to obtain target current digital signals;
s232, the server acquires a target current digital signal from the acquisition end through the wireless transmission module;
s233, the server converts the value of the target current digital signal and a preset glucose calibration algorithm to obtain a real-time blood glucose value;
s234, when the real-time blood sugar value exceeds a preset value range and the reminding is not closed within a preset time length, the server generates prompt information and sends the prompt information to the terminal equipment to carry out abnormal blood sugar reminding;
and S234, when the server receives the closing reminding information fed back by the terminal equipment and the closing times reach the preset times within the preset duration, generating the reminding information and sending the reminding information to the terminal equipment for reminding equipment faults.
Specifically, the terminal device reminds in a voice, vibration and interface prompting mode, wherein in order to distinguish blood sugar abnormity reminding and device fault reminding, the terminal device distinguishes reminding through different reminding contents, for example, the terminal device reminds blood sugar abnormity through voice, and device fault reminding is carried out through vibration. Of course, the terminal device can perform blood sugar abnormality reminding and device failure reminding by vibration, and only the vibration frequencies are different, and other ways of distinguishing and reminding different reminding contents are within the protection scope of the present invention, and will not be described in detail herein.
The real-time blood sugar value generally does not exceed a preset blood sugar maximum value and a preset blood sugar minimum value of a medical clinical observation value, and at the minimum value, because the brain cannot obtain blood sugar supply, a person can die after being unconscious, and if the measured value frequently exceeds a preset upper limit value and a preset lower limit value (namely the preset value range of the invention), the server can generate prompt information and send the prompt information to the terminal equipment for reminding blood sugar abnormity. If the real situation of the patient is that no critical phenomenon exists and the self-feeling physical state is normal, the reminding sent by the terminal equipment can be turned off, the server starts timing at the initial moment of the abnormal reminding of the excessive blood sugar, and if the number of times of the terminal equipment feedback turning-off reminding is received within the preset time period, the server generates prompt information and sends the prompt information to the terminal equipment to carry out equipment fault reminding so as to remind the user of timely maintaining or replacing the acquisition end.
In an embodiment of the present invention, as shown in fig. 8, a semi-implantable optical blood glucose monitoring method includes:
s241, collecting optical reflection signals by an infrared receiving and transmitting device implanted under the skin through a collecting end, and carrying out photoelectric conversion on the optical reflection signals to obtain target current digital signals;
s242, the server acquires a target current digital signal from the acquisition end through the wireless transmission module;
s243, the server converts the value of the target current digital signal and a preset glucose calibration algorithm to obtain a real-time blood glucose value;
s244 the server generates and sends first prompt information to the terminal equipment to remind the terminal equipment of excessive blood sugar when the real-time blood sugar value is higher than the preset maximum blood sugar value;
s245 the server acquires the input blood glucose event information from the terminal equipment and calculates the insulin demand according to the real-time blood glucose value and the blood glucose event information;
s246, the server generates an injection instruction according to the insulin demand when acquiring the injection confirmation information sent by the terminal equipment, and sends the injection instruction to an execution end which is arranged on the body surface and is provided with a micro pump and a liquid storage cavity;
s247, injecting the insulin medicament in the micro pump into the body of the user by the execution end according to the injection instruction;
s248, the server generates and sends second prompt information to the terminal equipment to remind that the blood sugar is too low when the real-time blood sugar value is lower than the preset blood sugar minimum value;
and when the S249 server receives the closing reminding information fed back by the terminal equipment and the closing times reach the preset times within the preset time, generating the reminding information and sending the reminding information to the terminal equipment to remind the equipment of the fault.
Specifically, the terminal device may obtain information about related events that affect blood glucose changes, that is, blood glucose event information, where the information about blood glucose events includes, but is not limited to, event types corresponding to blood glucose activity events and occurrence times and numbers corresponding to the event types, the information about blood glucose activity events includes, but is not limited to, meals, medicines, and sports, and many similar activity events may be included, such as watching a stimulating movie, singing a song, running, and the like. The blood glucose event information can be recorded to facilitate doctors to analyze the illness state and give suggestions when necessary, in addition, when the blood glucose event information is accumulated to a certain amount of data, intelligent life planning, intelligent life suggestions and intelligent life reminders can be made, the data can be used for medical research, and research results can serve more people.
Diabetes mellitus is a chronic metabolic disease, and the occurrence, development, prevention and treatment of diabetes mellitus are closely related to dietary nutrition. The nutrition treatment is the basis of the diabetes comprehensive treatment, the diabetes diet emphasizes individuation, but the data of real-time monitoring is not taken as the basis, the nutrition treatment is difficult to be really realized, and the nutrition treatment is mainly divided according to groups, such as gestational diabetes groups, elderly groups, children diabetes groups and the like. Personalized dietary nutrition regimens are also referred to at present, but are not easy to do without real-time monitoring and accumulated data. Therefore, after accumulating for a certain time based on obtaining the blood glucose event information, the patient can be provided with an intelligent life plan through the individualized blood glucose event information and physiological state information of the patient, which comprises the following contents:
(1) scheduling work and rest time: different blood sugar values of patients in different time periods and different risks in different time periods have different influences on the blood sugar due to different activity events, such as a certain patient loving table tennis, and after accumulating data for a certain time (assuming that 2 weeks, along with the accumulation of data, intelligent planning is more and more accurate), a reasonable activity arrangement suggestion can be given so as to suggest activity arrangement suggestions such as activity duration and playing time period of a day for the patient;
(2) personalized nutritional regimen recommendations: the physiological state information of the patients is completely individualized data, the people in different areas have different eating habits, religious beliefs and other subsidized eating habits, and the patients in the same area also have different tastes. The correlation between the blood sugar condition, physical condition, daily activities and nutritional requirements of patients is a great deal of research in medicine. For example, the same diet has different influences on blood sugar values of different patients, and after certain data are accumulated, personalized targeted suggestions can be intelligently given to suggest food intake and food intake types so as to meet the taste of the patients and improve the life quality of the patients as much as possible on the premise of ensuring that the blood sugar content of the patients is maintained at a normal level.
When the real-time blood sugar value exceeds the preset value range, namely when the real-time blood sugar value is lower than the preset blood sugar minimum value, if the second prompt message is generated during the closing prompt within the preset time length and is sent to the terminal equipment to carry out the too low blood sugar prompt, the user can conveniently take food and supplement glucose in time. When the real-time blood sugar value is higher than the maximum value of the preset blood sugar, if the real-time blood sugar value is not closed for reminding, first prompt information is generated and sent to the terminal equipment for reminding of excessive blood sugar, in addition, the terminal equipment acquires input blood sugar event information and reports the information to the server, then the server calculates the insulin demand according to the real-time blood sugar value and the blood sugar event information to obtain the insulin demand, when the server acquires the confirmed injection information of the user forwarded by the terminal equipment, the server generates an injection instruction according to the insulin demand, the injection instruction is sent to an execution end which is installed on the body surface and provided with a micropump and a liquid storage cavity, and the execution end injects insulin medicines in the micropump into the body of the user according to the injection instruction.
The execution end comprises a central processing unit for storing control programs and operation data and a processor of a storage element; a wireless communication module for sending and receiving injection instructions; a display for displaying the remaining amount of insulin medication to a user; a battery for providing power to the execution end; the insulin pump comprises a liquid storage cavity for storing insulin medicine and a micro pump for extracting the insulin medicine from the liquid storage cavity and injecting the insulin medicine into a user body.
Preferably, the application software can be installed on the terminal equipment of the user such as a researcher, a doctor, a family member, a patient and a friend, and because of the privacy of the patient, if the blood sugar value needs to be shared to other people, the terminal equipment owner needs to share the login account password of the application software to other people.
The terminal equipment not only realizes core functions of dynamic monitoring, data query, waveform display and the like, but also can carry out intelligent statistical analysis on the monitored data, simplifies the operation of the patient, provides a more visual and concise feedback result for the patient, and can realize functions of dynamic monitoring, safe reminding, emergency call, emergency notification of family members and the like of the blood glucose data.
It will be apparent to those skilled in the art that, for convenience and brevity of description, only the above-described division of program modules is illustrated, and in practical applications, the above-described distribution of functions may be performed by different program modules, that is, the internal structure of the apparatus may be divided into different program units or modules to perform all or part of the above-described functions. Each program module in the embodiments may be integrated in one processing unit, or each unit may exist alone physically, or two or more units are integrated in one processing unit, and the integrated unit may be implemented in a form of hardware, or may be implemented in a form of software program unit. In addition, the specific names of the program modules are only used for distinguishing the program modules from one another, and are not used for limiting the protection scope of the application.
In one embodiment of the invention, a terminal device comprises a processor and a memory, wherein the memory is used for storing a computer program; and a processor for executing the computer program stored in the memory to implement the semi-implantable optical blood glucose monitoring method in the embodiment of the method corresponding to fig. 1-4.
In one embodiment of the invention, a server comprises a processor and a memory, wherein the memory is used for storing a computer program; and a processor for executing the computer program stored in the memory to implement the semi-implantable optical blood glucose monitoring method in the embodiment of the method corresponding to fig. 5 to 8.
The terminal device can be a desktop computer, a notebook computer, a palm computer, a tablet computer, a mobile phone, a man-machine interaction screen and the like.
The terminal device/server may include, but is not limited to, a processor, a memory. It will be appreciated by those skilled in the art that the foregoing is merely an example of a terminal device/server and is not intended to be limiting and may include more or less components than those shown, or some components may be combined, or different components, such as: the terminal device/server may also include input/output interfaces, display devices, network access devices, communication buses, communication interfaces, and the like. A communication interface and a communication bus, and may further comprise an input/output interface, wherein the processor, the memory, the input/output interface and the communication interface complete communication with each other through the communication bus. The memory stores a computer program, and the processor is used for executing the computer program stored on the memory to implement the semi-implantation type optical blood glucose monitoring method in the above method embodiment.
The processor may be a Single-chip microprocessor (a kind of integrated circuit chip) Central Processing Unit (CPU), or other general purpose processor, Digital Signal Processor (DSP), Application Specific Integrated Circuit (ASIC), Field Programmable Gate Array (FPGA) or other programmable logic device, discrete gate or transistor logic device, discrete hardware component, or the like. The general purpose processor may be a photo detection module or the processor may be any conventional processor or the like. If the terminal equipment is small-sized equipment such as a bracelet and a wrist ring, the processor preferably adopts a micro single chip microcomputer with low power consumption or an old-version DSP chip. If the terminal device is a non-small device such as a smart phone or a tablet, the processor may be a processor with high power consumption and large heat productivity, such as a CPU chip.
The memory may be an internal storage unit of the terminal device/server, such as: hard disk or memory of terminal device/server. The memory may also be an external storage device of the terminal device/server, such as: a plug-in hard disk, a Smart Media Card (SMC), a Secure Digital (SD) card, a flash memory card (FlashCard), etc. provided on the terminal device/server. Further, the memory may also include both internal and external storage units of the terminal device/server. The memory is used for storing computer programs and other programs and data required by the terminal device/server. The memory may also be used to temporarily store data that has been output or is to be output.
A communication bus is a circuit that connects the described elements and enables transmission between the elements. For example, the processor receives commands from other elements through the communication bus, decrypts the received commands, and performs calculations or data processing according to the decrypted commands. The memory may include program modules such as a kernel (kernel), middleware (middleware), an Application Programming Interface (API), and applications. The program modules may be comprised of software, firmware or hardware, or at least two of the same. The input/output interface forwards commands or data entered by a user via the input/output interface (e.g., sensor, keyboard, touch screen). The communication interface connects the terminal device/server with other network devices, user equipment, networks. For example, the communication interface may be connected to a network by wire or wirelessly to connect to external other network devices or user devices. The wireless communication may include at least one of: wireless fidelity (WiFi), Bluetooth (BT), Near Field Communication (NFC), Global Positioning Satellite (GPS) and cellular communications, among others. The wired communication may include at least one of: universal Serial Bus (USB), high-definition multimedia interface (HDMI), asynchronous transfer standard interface (RS-232), and the like. The network may be a telecommunications network and a communications network. The communication network may be a computer network, the internet of things, a telephone network. The terminal device/server may be connected to the network via a communication interface, and a protocol used by the terminal device/server to communicate with other network devices may be supported by at least one of an application, an Application Programming Interface (API), middleware, a kernel, and a communication interface.
In an embodiment of the present invention, a storage medium stores at least one instruction, and the instruction is loaded and executed by a processor to implement the operations performed by the corresponding embodiments of the semi-implantable optical blood glucose monitoring method. For example, the computer readable storage medium may be a read-only memory (ROM), a random-access memory (RAM), a compact disc read-only memory (CD-ROM), a magnetic tape, a floppy disk, an optical data storage device, and the like.
They may be implemented in program code that is executable by a computing device such that it is executed by the computing device, or separately, or as individual integrated circuit modules, or as a plurality or steps of individual integrated circuit modules. Thus, the present invention is not limited to any specific combination of hardware and software.
In the above embodiments, the descriptions of the respective embodiments have respective emphasis, and reference may be made to the related descriptions of other embodiments for parts that are not described or recited in detail in a certain embodiment.
Those of ordinary skill in the art will appreciate that the various illustrative elements and algorithm steps described in connection with the embodiments disclosed herein may be implemented as electronic hardware or combinations of computer software and electronic hardware. Whether such functionality is implemented as hardware or software depends upon the particular application and design constraints imposed on the implementation. Skilled artisans may implement the described functionality in varying ways for each particular application, but such implementation decisions should not be interpreted as causing a departure from the scope of the present application.
In the embodiments provided in the present application, it should be understood that the disclosed apparatus/terminal device/server and method may be implemented in other ways. For example, the above-described apparatus/terminal device/server embodiments are merely illustrative, and for example, a module or a unit may be divided into only one logical function, and may be implemented in other ways, for example, multiple units or components may be combined or integrated into another system, or some features may be omitted, or not executed. In addition, the shown or discussed mutual coupling or direct coupling or communication connection may be an indirect coupling or communication connection of some interfaces, devices or units, and may be in an electrical, mechanical or other form.
Units described as separate parts may or may not be physically separate, and parts displayed as units may or may not be physical units, may be located in one place, or may be distributed on a plurality of network units. Some or all of the units can be selected according to actual needs to achieve the purpose of the solution of the embodiment.
In addition, functional units in the embodiments of the present application may be integrated into one processing unit, or each unit may exist alone physically, or two or more units are integrated into one unit. The integrated unit can be realized in a form of hardware, and can also be realized in a form of a software functional unit.
The integrated modules/units, if implemented in the form of software functional units and sold or used as separate products, may be stored in a computer readable storage medium. Based on such understanding, all or part of the flow in the method according to the embodiments of the present invention may also be implemented by sending instructions to relevant hardware through a computer program, where the computer program may be stored in a computer readable storage medium, and when the computer program is executed by a processor, the computer program may implement the steps of the embodiments of the method. Wherein the computer program comprises: computer program code which may be in the form of source code, object code, an executable file or some intermediate form, etc. The computer-readable storage medium may include: any entity or device capable of carrying computer program code, recording medium, usb disk, removable hard disk, magnetic disk, optical disk, computer memory, Read-only memory (ROM), Random Access Memory (RAM), electrical carrier wave signals, telecommunications signals, software distribution medium, and the like. It should be noted that the content of the computer readable storage medium can be increased or decreased according to the requirements of the legislation and patent practice in the jurisdiction, for example: in certain jurisdictions, in accordance with legislation and patent practice, the computer-readable medium does not include electrical carrier signals and telecommunications signals.
It should be noted that the above embodiments can be freely combined as necessary. The foregoing is only a preferred embodiment of the present invention, and it should be noted that, for those skilled in the art, various modifications and decorations can be made without departing from the principle of the present invention, and these modifications and decorations should also be regarded as the protection scope of the present invention.
Claims (10)
1. A semi-implantable optical blood glucose monitoring method is characterized by comprising the following steps:
the collecting end collects optical reflection signals through an infrared receiving and transmitting device implanted under the skin and carries out photoelectric conversion on the optical reflection signals to obtain target current digital signals;
the terminal equipment receives a target current digital signal sent by a wireless communication module of the acquisition end directly or through a server;
and the terminal equipment converts the value according to a preset glucose calibration algorithm and the target current digital signal to obtain the real-time blood glucose value.
2. The semi-implantable optical blood glucose monitoring method according to claim 1, wherein the step of converting the terminal device into the real-time blood glucose value according to a preset glucose calibration algorithm and the value of the target current digital signal comprises:
the terminal device displays the real-time blood glucose values and/or the retrospective blood glucose values.
3. The semi-implantable optical blood glucose monitoring method according to claim 1, wherein the step of converting the terminal device into the real-time blood glucose value according to a preset glucose calibration algorithm and the value of the target current digital signal further comprises:
the terminal equipment generates prompt information to remind abnormal blood sugar when the real-time blood sugar value exceeds a preset numerical range;
and if the closing times of the terminal equipment for reminding the abnormal blood glucose reach the preset times within the preset time, generating prompt information to remind equipment faults.
4. The semi-implantable optical blood glucose monitoring method according to claim 3, wherein the terminal device generates a prompt message to prompt abnormal blood glucose when the real-time blood glucose value exceeds a preset numerical range, and the method comprises the following steps:
the terminal equipment carries out blood sugar excess reminding when the real-time blood sugar value is higher than a preset blood sugar maximum value;
when the real-time blood glucose value is lower than a preset blood glucose minimum value, the terminal equipment reminds of too low blood glucose;
the terminal equipment comprises the following steps after the blood sugar excess reminding is carried out:
the terminal equipment acquires the input blood glucose event information and calculates the insulin demand according to the real-time blood glucose value and the blood glucose event information;
the terminal equipment generates an injection instruction according to the insulin demand when acquiring the injection confirmation information, and sends the injection instruction to an execution end which is arranged on the body surface and is provided with a micro pump and a liquid storage cavity;
and the execution end injects the insulin medicament in the micro pump into the body of the user according to the injection instruction.
5. A semi-implantable optical blood glucose monitoring method is characterized by comprising the following steps:
the collecting end collects optical reflection signals through an infrared receiving and transmitting device implanted under the skin and carries out photoelectric conversion on the optical reflection signals to obtain target current digital signals;
the server acquires a target current digital signal from the acquisition end through the wireless transmission module;
and the server converts the digital value of the target current digital signal according to a preset glucose calibration algorithm to obtain a real-time blood glucose value.
6. The semi-implantable optical blood glucose monitoring method according to claim 5, wherein the server comprises steps of, after converting the values of the target current digital signal and the preset glucose calibration algorithm to obtain the real-time blood glucose value:
and the server sends the real-time blood glucose value to the terminal equipment, and the terminal equipment displays the real-time blood glucose value and/or the retrospective blood glucose value.
7. The semi-implantable optical blood glucose monitoring method according to claim 5, wherein the server further comprises, after converting the digital values of the target current digital signal and the preset glucose calibration algorithm to obtain the real-time blood glucose value, the steps of:
the server generates prompt information when the real-time blood glucose value exceeds a preset numerical range and sends the prompt information to the terminal equipment to remind of blood glucose abnormity;
and the server generates prompt information and sends the prompt information to the terminal equipment to remind equipment faults when receiving the closing prompt information fed back by the terminal equipment and the closing times reach the preset times within the preset time.
8. The semi-implantable optical blood glucose monitoring method of claim 7, wherein the server generating a prompt message when the real-time blood glucose value exceeds a preset numerical range comprises the steps of:
the server generates and sends first prompt information to the terminal equipment to remind the terminal equipment of excessive blood sugar when the real-time blood sugar value is higher than a preset maximum blood sugar value;
the server generates and sends second prompt information to the terminal equipment to remind the user of the too low blood sugar when the real-time blood sugar value is lower than a preset minimum blood sugar value;
the terminal equipment comprises the following steps after the terminal equipment reminds of excessive blood sugar:
the server acquires the input blood glucose event information from the terminal equipment and calculates the insulin demand according to the real-time blood glucose value and the blood glucose event information;
the server generates an injection instruction according to the insulin demand when acquiring the injection confirmation information sent by the terminal equipment, and sends the injection instruction to an execution end which is arranged on the body surface and is provided with a micro pump and a liquid storage cavity;
and the execution end injects the insulin medicament in the micro pump into the body of the user according to the injection instruction.
9. A terminal device, comprising a processor, a memory and a computer program stored in the memory and executable on the processor, wherein the processor is configured to execute the computer program stored in the memory to perform the operations performed by the semi-implantable optical blood glucose monitoring method according to any one of claims 1 to 4.
10. A server comprising a processor, a memory, and a computer program stored in and executable on the memory, the processor configured to execute the computer program stored in the memory to perform the operations performed by the semi-implantable optical blood glucose monitoring method according to any one of claims 5-8.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010449335.7A CN111603176A (en) | 2020-05-25 | 2020-05-25 | Semi-implanted optical blood glucose monitoring method, terminal equipment and server |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010449335.7A CN111603176A (en) | 2020-05-25 | 2020-05-25 | Semi-implanted optical blood glucose monitoring method, terminal equipment and server |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN111603176A true CN111603176A (en) | 2020-09-01 |
Family
ID=72193888
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010449335.7A Pending CN111603176A (en) | 2020-05-25 | 2020-05-25 | Semi-implanted optical blood glucose monitoring method, terminal equipment and server |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111603176A (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111920423A (en) * | 2020-10-16 | 2020-11-13 | 湖州美奇医疗器械有限公司 | Blood glucose data monitoring system, blood glucose data communication monitoring method and application method |
| CN114099847A (en) * | 2021-11-05 | 2022-03-01 | 长电科技管理有限公司 | Blood sugar control cavity packaging device and control method thereof |
| CN115337502A (en) * | 2022-09-20 | 2022-11-15 | 青岛海诺生物工程有限公司 | Blood glucose monitoring and controlling system and blood glucose monitoring and controlling method |
| CN117562520A (en) * | 2024-01-02 | 2024-02-20 | 广州市碳码科技有限责任公司 | Monitoring system for human physiological parameters and monitoring report generation method |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101022760A (en) * | 2004-05-20 | 2007-08-22 | 数字安吉尔公司 | Embedded bio-sensor system |
| CN101548892A (en) * | 2009-04-29 | 2009-10-07 | 天津市先石光学技术有限公司 | Implanted in-vivo continuous blood sugar monitor |
| CN102333478A (en) * | 2008-12-24 | 2012-01-25 | 葡萄糖传感器公司 | Implantable optical glucose sensing |
| CN107715230A (en) * | 2017-10-12 | 2018-02-23 | 微泰医疗器械(杭州)有限公司 | Insulin pump individuation configuration optimization system and method based on high in the clouds big data |
| CN110121561A (en) * | 2016-12-27 | 2019-08-13 | 普罗菲尤萨股份有限公司 | Near-infrared glucose sensor |
-
2020
- 2020-05-25 CN CN202010449335.7A patent/CN111603176A/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101022760A (en) * | 2004-05-20 | 2007-08-22 | 数字安吉尔公司 | Embedded bio-sensor system |
| CN102333478A (en) * | 2008-12-24 | 2012-01-25 | 葡萄糖传感器公司 | Implantable optical glucose sensing |
| CN101548892A (en) * | 2009-04-29 | 2009-10-07 | 天津市先石光学技术有限公司 | Implanted in-vivo continuous blood sugar monitor |
| CN110121561A (en) * | 2016-12-27 | 2019-08-13 | 普罗菲尤萨股份有限公司 | Near-infrared glucose sensor |
| CN107715230A (en) * | 2017-10-12 | 2018-02-23 | 微泰医疗器械(杭州)有限公司 | Insulin pump individuation configuration optimization system and method based on high in the clouds big data |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111920423A (en) * | 2020-10-16 | 2020-11-13 | 湖州美奇医疗器械有限公司 | Blood glucose data monitoring system, blood glucose data communication monitoring method and application method |
| CN111920423B (en) * | 2020-10-16 | 2020-12-22 | 湖州美奇医疗器械有限公司 | Blood glucose data monitoring system, blood glucose data communication monitoring method and application method |
| CN114099847A (en) * | 2021-11-05 | 2022-03-01 | 长电科技管理有限公司 | Blood sugar control cavity packaging device and control method thereof |
| CN115337502A (en) * | 2022-09-20 | 2022-11-15 | 青岛海诺生物工程有限公司 | Blood glucose monitoring and controlling system and blood glucose monitoring and controlling method |
| CN115337502B (en) * | 2022-09-20 | 2024-06-14 | 青岛海诺生物工程有限公司 | Blood sugar monitoring control system |
| CN117562520A (en) * | 2024-01-02 | 2024-02-20 | 广州市碳码科技有限责任公司 | Monitoring system for human physiological parameters and monitoring report generation method |
| CN117562520B (en) * | 2024-01-02 | 2024-04-19 | 广州市碳码科技有限责任公司 | Monitoring system for human physiological parameters and monitoring report generation method |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2019217879B2 (en) | System and method for decision support | |
| US12014821B2 (en) | Systems and methods for managing glycemic variability | |
| CN111603176A (en) | Semi-implanted optical blood glucose monitoring method, terminal equipment and server | |
| CN102639058B (en) | For the analyte test method and apparatus of diabetes management | |
| US20180197628A1 (en) | Systems, devices, and methods for experiential medication dosage calculations | |
| RU2285442C2 (en) | Personal system for controlling health state | |
| US8721543B2 (en) | Data analytics system | |
| KR101107062B1 (en) | System for monitoring and managing body weight and other physiological conditions including iterative and personalized planning, intervention and reporting capability | |
| CA2538758C (en) | System for monitoring and managing body weight and other physiological conditions including iterative and personalized planning, intervention and reporting capability | |
| US20080139910A1 (en) | Analyte sensor and method of using the same | |
| US20030208113A1 (en) | Closed loop glycemic index system | |
| CA2842423A1 (en) | Health meter | |
| CN111603175A (en) | Subcutaneous semi-implanted blood glucose monitoring method, terminal equipment and server | |
| WO2020252317A1 (en) | Portable health monitoring apparatus, system, and method | |
| CN211719264U (en) | Intelligent daily life habit management service system | |
| CN115052516A (en) | Decision support and therapy management system | |
| KR20220060125A (en) | Method for predicting blood glucose using peak blood glucose level and food proposal system | |
| WO2023124316A1 (en) | Glucose monitoring system | |
| US20240138776A1 (en) | Wearable non-invasive blood glucose monitoring system | |
| CN215815209U (en) | Blood glucose meter that insulin dosage decision-making was reminded | |
| CN117854679B (en) | Preinterventional diet behavior management system and management method thereof | |
| WO2024193591A1 (en) | Blood glucose monitoring method, graphical interface, and related apparatus | |
| Bhondge et al. | Integrating portable wearable health technology in patients care | |
| Franchini | Automatic Continuous Glucose Monitoring in Paediatric Patients Suffering from Type One Diabetes | |
| WO2023211986A1 (en) | Systems, devices, and methods for meal-related analyte response monitoring |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20200901 |